Asymchem Laboratories Tian Jin Co Ltd (002821) - Net Assets
Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) has net assets worth CN¥17.65 Billion CNY (≈ $2.58 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥20.28 Billion ≈ $2.97 Billion USD) and total liabilities (CN¥2.63 Billion ≈ $385.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Asymchem Laboratories Tian Jin Co Ltd (002821) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥17.65 Billion |
| % of Total Assets | 87.02% |
| Annual Growth Rate | 28.24% |
| 5-Year Change | 39.94% |
| 10-Year Change | 862.7% |
| Growth Volatility | 36.53 |
Asymchem Laboratories Tian Jin Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002821 total assets for the complete picture of this company's asset base.
Annual Net Assets for Asymchem Laboratories Tian Jin Co Ltd (2011–2025)
The table below shows the annual net assets of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2025. For live valuation and market cap data, see 002821 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥17.65 Billion ≈ $2.58 Billion |
+4.65% |
| 2024-12-31 | CN¥16.86 Billion ≈ $2.47 Billion |
-3.70% |
| 2023-12-31 | CN¥17.51 Billion ≈ $2.56 Billion |
+11.56% |
| 2022-12-31 | CN¥15.70 Billion ≈ $2.30 Billion |
+24.46% |
| 2021-12-31 | CN¥12.61 Billion ≈ $1.85 Billion |
+110.53% |
| 2020-12-31 | CN¥5.99 Billion ≈ $876.49 Million |
+96.68% |
| 2019-12-31 | CN¥3.05 Billion ≈ $445.65 Million |
+21.31% |
| 2018-12-31 | CN¥2.51 Billion ≈ $367.38 Million |
+16.50% |
| 2017-12-31 | CN¥2.16 Billion ≈ $315.35 Million |
+17.57% |
| 2016-12-31 | CN¥1.83 Billion ≈ $268.22 Million |
+95.62% |
| 2015-12-31 | CN¥937.02 Million ≈ $137.12 Million |
+19.34% |
| 2014-12-31 | CN¥785.17 Million ≈ $114.90 Million |
+14.44% |
| 2013-12-31 | CN¥686.10 Million ≈ $100.40 Million |
+12.83% |
| 2012-12-31 | CN¥608.06 Million ≈ $88.98 Million |
+12.13% |
| 2011-12-31 | CN¥542.26 Million ≈ $79.35 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Asymchem Laboratories Tian Jin Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10999.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥8.82 Billion | 49.99% |
| Other Components | CN¥8.82 Billion | 50.01% |
| Total Equity | CN¥17.64 Billion | 100.00% |
Asymchem Laboratories Tian Jin Co Ltd Competitors by Market Cap
The table below lists competitors of Asymchem Laboratories Tian Jin Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
$6.02 Billion |
|
Hyundai Mipo Dockyard
KO:010620
|
$6.03 Billion |
|
United Integrated Services Co Ltd
TW:2404
|
$6.03 Billion |
|
Amdocs Limited
F:AOS
|
$6.03 Billion |
|
Bank Millennium S.A.
WAR:MIL
|
$6.02 Billion |
|
The People's Insurance Company (Group) of China Limited
F:PIR
|
$6.02 Billion |
|
Hyundai Construction Equipment Co Ltd
KO:267270
|
$6.02 Billion |
|
Ramsay Health Care Ltd
AU:RHC
|
$6.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Asymchem Laboratories Tian Jin Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,845,385,169 to 17,635,098,689, a change of 789,713,520 (4.7%).
- Net income of 1,132,569,776 contributed positively to equity growth.
- Dividend payments of 395,066,122 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.13 Billion | +6.42% |
| Dividends Paid | CN¥395.07 Million | -2.24% |
| Other Changes | CN¥52.21 Million | +0.3% |
| Total Change | CN¥- | 4.69% |
Book Value vs Market Value Analysis
This analysis compares Asymchem Laboratories Tian Jin Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 61.10x to 2.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥2.02 | CN¥123.58 | x |
| 2012-12-31 | CN¥2.23 | CN¥123.58 | x |
| 2013-12-31 | CN¥2.50 | CN¥123.58 | x |
| 2014-12-31 | CN¥2.96 | CN¥123.58 | x |
| 2015-12-31 | CN¥3.51 | CN¥123.58 | x |
| 2016-12-31 | CN¥6.84 | CN¥123.58 | x |
| 2017-12-31 | CN¥6.42 | CN¥123.58 | x |
| 2018-12-31 | CN¥7.79 | CN¥123.58 | x |
| 2019-12-31 | CN¥9.43 | CN¥123.58 | x |
| 2020-12-31 | CN¥18.25 | CN¥123.58 | x |
| 2021-12-31 | CN¥36.94 | CN¥123.58 | x |
| 2022-12-31 | CN¥42.65 | CN¥123.58 | x |
| 2023-12-31 | CN¥48.23 | CN¥123.58 | x |
| 2024-12-31 | CN¥47.75 | CN¥123.58 | x |
| 2025-12-31 | CN¥48.91 | CN¥123.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Asymchem Laboratories Tian Jin Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.98%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.15x
- Recent ROE (6.42%) is below the historical average (13.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 12.89% | 16.11% | 0.51x | 1.58x | CN¥14.65 Million |
| 2012 | 10.72% | 14.20% | 0.51x | 1.47x | CN¥4.07 Million |
| 2013 | 11.86% | 13.77% | 0.59x | 1.45x | CN¥11.75 Million |
| 2014 | 13.65% | 14.21% | 0.68x | 1.42x | CN¥27.24 Million |
| 2015 | 17.42% | 18.49% | 0.65x | 1.44x | CN¥65.42 Million |
| 2016 | 14.41% | 22.91% | 0.45x | 1.39x | CN¥77.30 Million |
| 2017 | 16.59% | 23.98% | 0.54x | 1.28x | CN¥135.53 Million |
| 2018 | 17.06% | 23.34% | 0.58x | 1.27x | CN¥177.24 Million |
| 2019 | 18.19% | 22.51% | 0.65x | 1.23x | CN¥249.31 Million |
| 2020 | 12.02% | 22.95% | 0.44x | 1.20x | CN¥120.76 Million |
| 2021 | 8.48% | 23.08% | 0.31x | 1.20x | CN¥-191.73 Million |
| 2022 | 21.10% | 32.27% | 0.56x | 1.17x | CN¥1.74 Billion |
| 2023 | 12.98% | 28.99% | 0.40x | 1.13x | CN¥520.84 Million |
| 2024 | 5.63% | 16.35% | 0.30x | 1.15x | CN¥-735.59 Million |
| 2025 | 6.42% | 16.98% | 0.33x | 1.15x | CN¥-630.94 Million |
Industry Comparison
This section compares Asymchem Laboratories Tian Jin Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,264,126,017
- Average return on equity (ROE) among peers: 7.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Asymchem Laboratories Tian Jin Co Ltd (002821) | CN¥17.65 Billion | 12.89% | 0.15x | $6.02 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $449.00 Million | 0.82% | 0.52x | $456.85 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.10 Billion | 6.29% | 0.12x | $467.03 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $2.00 Billion |
| Hualan Biological EngineeringInc (002007) | $13.42 Billion | 11.04% | 0.20x | $3.89 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $256.72 Million | 9.82% | 0.22x | $1.36 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $5.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.57 Billion | 2.25% | 0.61x | $575.82 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.22 Billion | 22.23% | 0.73x | $1.93 Billion |
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more